Rayner
Cary E. Dawes has extensive experience in leadership roles within the sales and banking sectors. Currently serving as the Chief Sales Execution Officer at Rayner since July 2005, Cary E. Dawes also held the positions of VP International and VP International & NED at Rayner Surgical. Prior to this, Cary E. Dawes worked at Barclays Bank from 2000 to 2007 as an Area Director, showcasing a strong background in international business and sales strategy.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.